Key Highlights

  • Helus Pharma reported 12-month treatment outcomes from its Phase 1/2a trial of HLP003 in major depressive disorder.
  • Data included safety observations and reports of subjective psychedelic effects.
  • HLP003 is a modified psilocin derivative being developed as a potential add-on therapy for MDD.
  • The company's Phase 3 PARADIGM trial is already active and expanding the drug's evidence base.
  • Shares closed up 10% at $13.66 following the update.

Article

Helus Pharma (NASDAQ: HELP) shares rose 10% to close at $13.66 after the company released updated 12-month findings from its Phase 1/2a trial of HLP003, a treatment candidate for major depressive disorder, or MDD. The update covered longer-term treatment outcomes, safety observations, and notes on the subjective psychedelic effects patients experienced during dosing — a category of data that carries particular weight in this emerging drug class.

HLP003 is described as a modified psilocin derivative. Psilocin is the active compound the body produces after metabolizing psilocybin, the substance found in so-called 'magic mushrooms' that has drawn growing clinical interest for mental health applications in recent years. By working with a modified version of this compound, Helus Pharma appears to be aiming for a treatment profile that retains therapeutic benefit while potentially offering a more controlled or differentiated safety and effects profile compared to unmodified psychedelic compounds.

The 12-month data point itself is notable for its duration. Much of the psychedelic-therapy research to date has focused on shorter observation windows immediately following treatment. Longer-term outcome data — assuming it holds up — helps address a central question for this entire treatment category: does the benefit from psychedelic-assisted therapy actually last, or does it fade over time in a way that requires repeated dosing?

The company is positioning HLP003 specifically as a potential add-on therapy for MDD, rather than a standalone replacement for existing antidepressants. That's a meaningful distinction. Add-on positioning can offer a faster and more pragmatic path to clinical adoption, since it doesn't require physicians to abandon established first-line treatments — it simply asks them to consider layering HLP003 on top for patients who aren't achieving adequate response with current standard-of-care options.

Supporting that strategy, the company's Phase 3 PARADIGM trial is already underway, expanding the evidence base for HLP003 beyond the earlier-stage data. Having a pivotal trial actively enrolling while simultaneously reporting supportive longer-term data from the earlier study gives the company a continuous stream of potential updates for investors to track over the coming quarters, rather than a long gap between catalysts.

Given the relatively favorable market reaction, investors will likely be watching for further updates on PARADIGM's enrollment progress and any interim data, along with additional detail on how regulators are viewing psilocin-derivative therapies as this niche but rapidly evolving category continues to mature.